Fundamental Analysis of BIOHAVEN LTD(NYSE:BHVN) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BHVN. BHVN was compared to 565 industry peers in the Biotechnology industry. While BHVN has a great health rating, there are worries on its profitability. BHVN has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BHVN has reported negative net income.

In the past year BHVN has reported a negative cash flow from operations.

In the past 5 years BHVN always reported negative net income.

BHVN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BHVN's Return On Assets of -157.55% is on the low side compared to the rest of the industry. BHVN is outperformed by 86.48% of its industry peers.

BHVN has a worse Return On Equity (-254.53%) than 71.53% of its industry peers.

		Industry Rank	Sector Rank
ROA	-157.55%
ROE	-254.53%
ROIC	N/A

ROA(3y)-105.39%

ROA(5y)-115.24%

ROE(3y)-272.45%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BHVN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, BHVN has more shares outstanding

The number of shares outstanding for BHVN has been increased compared to 5 years ago.

BHVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 3.32 indicates that BHVN is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 3.32, BHVN is in the better half of the industry, outperforming 76.51% of the companies in the same industry.

BHVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	3.32

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

BHVN has a Current Ratio of 2.89. This indicates that BHVN is financially healthy and has no problem in meeting its short term obligations.

BHVN has a Current ratio of 2.89. This is in the lower half of the industry: BHVN underperforms 66.55% of its industry peers.

BHVN has a Quick Ratio of 2.89. This indicates that BHVN is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 2.89, BHVN is not doing good in the industry: 64.59% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.89
Quick Ratio	2.89

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BHVN have decreased strongly by -30.40% in the last year.

EPS 1Y (TTM)-30.4%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-13.33%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.15% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-58.43%

EPS Next 2Y-5.98%

EPS Next 3Y0.73%

EPS Next 5Y5.15%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BHVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BHVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.98%

EPS Next 3Y0.73%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BHVN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOHAVEN LTD

NYSE:BHVN (12/23/2024, 10:34:04 AM)

35.98

-0.28 (-0.77%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/amc

Earnings (Next)N/A N/A

Inst Owners81.55%

Inst Owner Change0.9%

Ins Owners11.84%

Ins Owner Change0.05%

Market Cap3.64B

Analysts87.62

Price Target65.44 (81.88%)

Short Float %9.18%

Short Ratio9.29

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-50.03%

Min EPS beat(2)-101.89%

Max EPS beat(2)1.84%

EPS beat(4)1

Avg EPS beat(4)-40.86%

Min EPS beat(4)-101.89%

Max EPS beat(4)1.84%

EPS beat(8)2

Avg EPS beat(8)-39.78%

EPS beat(12)3

Avg EPS beat(12)-38.87%

EPS beat(16)3

Avg EPS beat(16)-34.76%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.65%

PT rev (3m)10.4%

EPS NQ rev (1m)0.01%

EPS NQ rev (3m)4.22%

EPS NY rev (1m)1%

EPS NY rev (3m)-142.51%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-16.72%

Revenue NY rev (1m)-7.14%

Revenue NY rev (3m)-82.31%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	11.51
P/tB	12.28
EV/EBITDA	N/A

EPS(TTM)-9.35

EYN/A

EPS(NY)-6.36

Fwd EYN/A

FCF(TTM)-5.25

FCFYN/A

OCF(TTM)-5.21

OCFYN/A

SpS0

BVpS3.13

TBVpS2.93

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-157.55%
ROE	-254.53%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-105.39%

ROA(5y)-115.24%

ROE(3y)-272.45%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	61.32%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.89
Quick Ratio	2.89
Altman-Z	3.32

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)182.81%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.4%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-13.33%

EPS Next Y-58.43%

EPS Next 2Y-5.98%

EPS Next 3Y0.73%

EPS Next 5Y5.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-71.23%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-103.71%

EBIT Next 3Y-11.54%

EBIT Next 5YN/A

FCF growth 1Y-26%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-26.69%

OCF growth 3YN/A

OCF growth 5YN/A

BIOHAVEN LTD (BHVN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens